← 返回前沿论文

癌症免疫治疗先进技术:聚焦胃肠道肿瘤

英文原题:Advanced Technologies for Cancer Immunotherapy: Focus on Gastrointestinal Cancers.

PubMed 2025/01/01(内容时间) Anticancer Agents Med Chem Q3 · IF 2.6(JCR 2025)

研究概要

免疫治疗正成为结直肠癌、胃癌和肝癌等胃肠道肿瘤的一种替代方法。

中文摘要

免疫疗法正成为结直肠癌、胃癌和肝癌等胃肠道肿瘤的替代治疗方式之一,其核心是利用免疫系统识别并清除癌细胞。一种重要方法是免疫检查点抑制剂,通过解除免疫系统的“刹车”使T细胞能够识别并攻击肿瘤细胞。另一种方法是嵌合抗原受体(CAR)T细胞疗法,通过改造患者T细胞,使其表达针对肿瘤相关抗原的受体。一些癌症疫苗在临床试验中显示出积极结果,尤其是在结直肠癌和胃癌领域。尽管已有进展,胃肠道肿瘤免疫治疗仍面临治疗耐药、患者选择所需生物标志物有限以及新靶点发现等挑战。本综述将介绍各类胃肠道肿瘤的不同免疫治疗方法,并详细讨论各方法的局限和优势。通过梳理不同免疫疗法及其利弊,本文为胃肠道肿瘤治疗的未来发展提供参考,既阐明免疫检查点抑制剂、CAR-T细胞疗法和癌症疫苗的进展,也强调了仍需进一步研究和创新解决的挑战。

展开英文摘要原文

Immunotherapy is becoming an alternative method for gastrointestinal cancers, such as colorectal, gastric, and liver cancers. This field of research focuses on utilizing the immune system to recognize and eliminate cancer cells. One important method is immune checkpoint inhibitors, which enable T cells to recognize and attack tumor cells by releasing the immune system's brakes. Chimeric antigen receptor (CAR) T-cell therapy is another approach that modifies a patient's T cells to express receptors specific to tumor-associated antigens. Some cancer vaccines have demonstrated positive results in clinical trials, particularly colorectal and gastric cancers. Despite progress, challenges exist in immunotherapy for gastrointestinal cancers, such as treatment resistance, limited biomarkers for patient selection, and identifying new targets. In this review, different immunotherapy methods for all types of gastrointestinal cancers will be studied, and the limitations and benefits of each will be discussed in detail. By delving into the various immunotherapy methods, their limitations, and benefits, this review offers valuable insights that could potentially shape the future of gastrointestinal cancer treatment. It not only sheds light on the promising advancements in immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines but also highlights the existing challenges that demand further research and innovation.

论文信息

作者
Ahangarzadeh S、Mohammadi E、Yaghoobi H、Shahzamani K、Alagheband Bahrami A、Arezumand R、Beikmohammadi L、Alibakhshi A
第一作者单位
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Iran
通讯作者单位
Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.Iran
文献类型
综述
期刊
Anti-cancer agents in medicinal chemistry2025
原文标识
PubMed 40211993 · DOI 10.2174/0118715206369319250402150638